Evaluation of partial beta-adrenoceptor agonist activity

被引:38
作者
Lipworth, BJ
Grove, A
机构
关键词
partial agonist; beta-adrenoceptor; exercise; asthma; salmeterol; salbutamol; fenoterol; celiprolol; carteolol;
D O I
10.1111/j.1365-2125.1997.tb00025.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A partial beta-adrenoceptor (beta-AR) agonist will exhibit opposite agonist and antagonist activity depending on the prevailing degree of adrenergic tone or the presence of a P-AR agonist with higher intrinsic activity. In vivo partial P-AR agonist activity will be evident at rest with low endogenous adrenergic tone, as for example with chronotopicity (beta(1)/beta(2)), inotropicity (beta(1)) or peripheral vasodilatation and finger tremor (beta(2)). beta-AR blocking drugs which have partial agonist activity may exhibit a better therapeutic profile when used for hypertension because of maintained cardiac output without increased systemic vascular resistance, along with an improved lipid profile. In the presence of raised endogenous adrenergic tone such as exercise or an exogenous full agonist, beta-AR subtype antagonist activity will become evident in terms of effects on exercise induced heart rate (beta(1)) and potassium (beta(2)) responses. Reduction of exercise heart rate will occur to a lesser degree in the case of a beta-adrenoceptor blocker with partial beta(1)-AR agonist activity compared with a beta-adrenoceptor blocker devoid of partial agonist activity. This may result in reduced therapeutic efficacy in the treatment of angina on effort when using beta-AR blocking drugs with partial beta(1)-AR agonist activity. Effects on exercise hyperkalaemia are determined by the balance between beta(2)-AR partial agonist activity and endogenous adrenergic activity. For predominantly beta(2)-AR agonists such as salmeterol and salbutamol, potentiation of exercise hyperkalaemia occurs. For predominantly beta(2)-AR antagonists such as carteolol, either potentiation or attenuation of exercise hyperkalaemia occurs at low and high doses respectively. beta(2)-AR partial agonist activity may also be expressed as antagonism in the presence of an exogenous full agonist, as for example attenuation of fenoterol induced responses by salmeterol. Studies are required to investigate whether this phenomenon is relevant in the setting of acute severe asthma.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 31 条
[1]   IMMEDIATE HEMODYNAMIC-EFFECTS OF A NOVEL PARTIAL AGONIST, BETA-1-ADRENOCEPTOR BLOCKING DRUG ICI-141292 AFTER INTRAVENOUS ADMINISTRATION TO HEALTHY-YOUNG VOLUNTEERS AND PATIENTS WITH ISCHEMIC-HEART-DISEASE [J].
BONDE, J ;
SVENDSEN, TL ;
LYNGBORG, K ;
MEHLSEN, J ;
TRAPJENSEN, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (01) :35-40
[2]   CELIPROLOL, ATENOLOL AND PROPRANOLOL - A COMPARISON OF PULMONARY EFFECTS IN ASTHMATIC-PATIENTS [J].
DOSHAN, HD ;
ROSENTHAL, RR ;
BROWN, R ;
SLUTSKY, A ;
APPLIN, WJ ;
CARUSO, FS .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1986, 8 :S105-S108
[3]   EFFECTS OF HIGH-DOSES OF CELIPROLOL IN ASTHMATIC-PATIENTS [J].
DOSHAN, HD ;
BROWN, R ;
APPLIN, WJ ;
KAPOOR, M ;
CARUSO, FS .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1986, 8 :S109-S111
[4]  
FORFANG K, 1989, EUR J CLIN PHARMACOL, V37, P23
[5]   EXPRESSION OF THE BETA(2) ADRENOCEPTOR PARTIAL AGONIST/ANTAGONIST ACTIVITY OF SALBUTAMOL IN STATES OF LOW AND HIGH ADRENERGIC TONE [J].
GROVE, A ;
MCFARLANE, LC ;
LIPWORTH, BJ .
THORAX, 1995, 50 (02) :134-138
[6]   Effects of prior treatment with salmeterol and formoterol on airway and systemic beta(2) responses to fenoterol [J].
Grove, A ;
Lipworth, BJ .
THORAX, 1996, 51 (06) :585-589
[7]   Evaluation of the beta(2) adrenoceptor agonist antagonist activity of formoterol and salmeterol [J].
Grove, A ;
Lipworth, BJ .
THORAX, 1996, 51 (01) :54-58
[8]   THE CARDIOVASCULAR EFFECTS OF XAMOTEROL, A BETA-1-ADRENOCEPTOR PARTIAL AGONIST, IN HEALTHY-VOLUNTEERS AT REST [J].
HASHIMOTO, T ;
SHIINA, A ;
TOYOOKA, T ;
HOSODA, S ;
KONDO, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (03) :259-265
[9]  
Hedner J, 1989, Pulm Pharmacol, V2, P155, DOI 10.1016/0952-0600(89)90040-9
[10]  
KALLSTROM BL, 1994, BRIT J PHARMACOL, V113, P687